-
1.
公开(公告)号:US08273870B2
公开(公告)日:2012-09-25
申请号:US13177316
申请日:2011-07-06
申请人: Roland Kreutzer , Stefan Limmer , Matthias John
发明人: Roland Kreutzer , Stefan Limmer , Matthias John
IPC分类号: C07H21/04
CPC分类号: C12N15/1131 , C12N15/111 , C12N2310/14 , C12N2310/53 , C12N2320/50
摘要: The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a mutant gene, comprising a first strand that has a complementary region that is complementary to at least a portion of an RNA transcript of at least part of the mutant target gene and a second strand of the dsRNA complementary or substantially complementary to the first strand. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target mutant gene, as well as for treating diseases caused by expression of the target gene. The invention also relates to methods for inhibiting the expression of a target mutant gene, as well as methods for treating diseases caused by the expression of the target gene.
摘要翻译: 本发明涉及用于抑制突变基因表达的双链核糖核酸(dsRNA),其包含第一链,该第一链具有与至少部分至少部分的RNA转录物的至少一部分互补的互补区 突变靶基因和与第一链互补或基本上互补的dsRNA的第二链。 本发明还涉及包含dsRNA和药学上可接受的载体的药物组合物。 药物组合物可用于抑制靶突变基因的表达,以及用于治疗由靶基因表达引起的疾病。 本发明还涉及抑制靶突变基因表达的方法,以及用于治疗由靶基因表达引起的疾病的方法。
-
2.
公开(公告)号:US20110287090A1
公开(公告)日:2011-11-24
申请号:US13177316
申请日:2011-07-06
申请人: Roland Kreutzer , Stefan Limmer , Matthias John
发明人: Roland Kreutzer , Stefan Limmer , Matthias John
IPC分类号: A61K31/713 , A61P35/02 , A61P35/00 , C07H21/02 , A61K9/127
CPC分类号: C12N15/1131 , C12N15/111 , C12N2310/14 , C12N2310/53 , C12N2320/50
摘要: The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a mutant gene, comprising a first strand that has a complementary region that is complementary to at least a portion of an RNA transcript of at least part of the mutant target gene and a second strand of the dsRNA complementary or substantially complementary to the first strand. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target mutant gene, as well as for treating diseases caused by expression of the target gene. The invention also relates to methods for inhibiting the expression of a target mutant gene, as well as methods for treating diseases caused by the expression of the target gene.
摘要翻译: 本发明涉及用于抑制突变基因表达的双链核糖核酸(dsRNA),其包含第一链,该第一链具有与至少部分至少部分的RNA转录物的至少一部分互补的互补区 突变靶基因和与第一链互补或基本上互补的dsRNA的第二链。 本发明还涉及包含dsRNA和药学上可接受的载体的药物组合物。 药物组合物可用于抑制靶突变基因的表达,以及用于治疗由靶基因表达引起的疾病。 本发明还涉及抑制靶突变基因表达的方法,以及用于治疗由靶基因表达引起的疾病的方法。
-
3.
公开(公告)号:US20100291194A1
公开(公告)日:2010-11-18
申请号:US12817009
申请日:2010-06-16
申请人: Roland Kreutzer , Stefan Limmer , Matthias John
发明人: Roland Kreutzer , Stefan Limmer , Matthias John
CPC分类号: C12N15/1131 , C12N15/111 , C12N2310/14 , C12N2310/53 , C12N2320/50
摘要: The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a mutant gene, comprising a complementary RNA strand having a complementary region that is substantially complementary to a portion of the mutant gene, and which is partially complementary to the corresponding wild-type gene. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target mutant gene, as well as for treating diseases caused by expression of the target gene. The invention also relates to methods for inhibiting the expression of a target mutant gene, as well as methods for treating diseases caused by the expression of the target gene.
摘要翻译: 本发明涉及用于抑制突变基因表达的双链核糖核酸(dsRNA),其包含互补RNA链,其具有与突变基因的一部分基本上互补的互补区,并且其部分互补于 相应的野生型基因。 本发明还涉及包含dsRNA和药学上可接受的载体的药物组合物。 药物组合物可用于抑制靶突变基因的表达,以及用于治疗由靶基因表达引起的疾病。 本发明还涉及抑制靶突变基因表达的方法,以及用于治疗由靶基因表达引起的疾病的方法。
-
公开(公告)号:US20080194512A1
公开(公告)日:2008-08-14
申请号:US11959936
申请日:2007-12-19
CPC分类号: C12N15/1131 , C12N2310/14 , C12N2310/53
摘要: The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is less that 30 nucleotides in length and which is substantially identical to at least a part of a 3′-untranslated region (3′-UTR) of a (+) strand RNA virus, such as HCV, as well as pharmaceutical compositions comprising the dsRNA, together with a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for treating infections and diseases caused by the replication or activity of the (+) strand RNA virus, as well as methods for inhibiting viral replication.
摘要翻译: 本发明涉及具有长度小于30个核苷酸的核苷酸序列的双链核糖核酸(dsRNA),并且其基本上与3'非翻译区(3'-UTR)的至少一部分相同 (+)链RNA病毒,例如HCV,以及包含dsRNA的药物组合物,以及药学上可接受的载体。 药物组合物可用于治疗由(+)链RNA病毒的复制或活性引起的感染和疾病以及用于抑制病毒复制的方法。
-
公开(公告)号:US07348314B2
公开(公告)日:2008-03-25
申请号:US10384512
申请日:2003-03-07
CPC分类号: C12N15/1131 , C12N2310/14 , C12N2310/53
摘要: The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is less that 30 nucleotides in length and which is substantially identical to at least a part of a 3′-untranslated region (3′-UTR) of a (+) strand RNA virus, such as HCV, as well as pharmaceutical compositions comprising the dsRNA, together with a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for treating infections and diseases caused by the replication or activity of the (+) strand RNA virus, as well as methods for inhibiting viral replication.
摘要翻译: 本发明涉及具有长度小于30个核苷酸的核苷酸序列的双链核糖核酸(dsRNA),并且其基本上与3'非翻译区(3'-UTR)的至少一部分相同 (+)链RNA病毒,例如HCV,以及包含dsRNA的药物组合物,以及药学上可接受的载体。 药物组合物可用于治疗由(+)链RNA病毒的复制或活性引起的感染和疾病以及用于抑制病毒复制的方法。
-
6.
公开(公告)号:US07994309B2
公开(公告)日:2011-08-09
申请号:US12817009
申请日:2010-06-16
申请人: Roland Kreutzer , Stefan Limmer , Matthias John
发明人: Roland Kreutzer , Stefan Limmer , Matthias John
IPC分类号: C07H21/04
CPC分类号: C12N15/1131 , C12N15/111 , C12N2310/14 , C12N2310/53 , C12N2320/50
摘要: The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a mutant gene, comprising a complementary RNA strand having a complementary region that is substantially complementary to a portion of the mutant gene, and which is partially complementary to the corresponding wild-type gene. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target mutant gene, as well as for treating diseases caused by expression of the target gene. The invention also relates to methods for inhibiting the expression of a target mutant gene, as well as methods for treating diseases caused by the expression of the target gene.
摘要翻译: 本发明涉及用于抑制突变基因表达的双链核糖核酸(dsRNA),其包含互补RNA链,其具有与突变基因的一部分基本上互补的互补区,并且其部分互补于 相应的野生型基因。 本发明还涉及包含dsRNA和药学上可接受的载体的药物组合物。 药物组合物可用于抑制靶突变基因的表达,以及用于治疗由靶基因表达引起的疾病。 本发明还涉及抑制靶突变基因表达的方法,以及用于治疗由靶基因表达引起的疾病的方法。
-
7.
公开(公告)号:US07763590B2
公开(公告)日:2010-07-27
申请号:US10384463
申请日:2003-03-07
申请人: Roland Kreutzer , Stefan Limmer , Matthias John
发明人: Roland Kreutzer , Stefan Limmer , Matthias John
IPC分类号: A61K48/00
CPC分类号: C12N15/1131 , C12N2310/14 , C12N2310/53
摘要: The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a mutant gene, comprising a complementary RNA strand having a complementary region that is substantially complementary to a portion of the mutant gene, and which is partially complementary to the corresponding wild-type gene. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target mutant gene, as well as for treating diseases caused by expression of the target gene. The invention also relates to methods for inhibiting the expression of a target mutant gene, as well as methods for treating diseases caused by the expression of the target gene.
摘要翻译: 本发明涉及用于抑制突变基因表达的双链核糖核酸(dsRNA),其包含互补RNA链,其具有与突变基因的一部分基本上互补的互补区,并且其部分互补于 相应的野生型基因。 本发明还涉及包含dsRNA和药学上可接受的载体的药物组合物。 药物组合物可用于抑制靶突变基因的表达,以及用于治疗由靶基因表达引起的疾病。 本发明还涉及抑制靶突变基因表达的方法,以及用于治疗由靶基因表达引起的疾病的方法。
-
公开(公告)号:US20050119202A1
公开(公告)日:2005-06-02
申请号:US10493686
申请日:2002-10-25
IPC分类号: C12N15/09 , A61K9/127 , A61K9/50 , A61K9/51 , A61K31/7105 , A61K31/713 , A61K38/00 , A61P31/14 , C07K14/18 , C07K14/82 , C12N15/113 , C12N15/40 , C12N15/51 , C12N15/88 , A61K48/00 , C07H21/02
CPC分类号: C12N15/1131 , A61K38/00 , C12N2310/14 , C12N2310/53
摘要: The invention concerns a medicament to treat a fibrotic disease, wherein the medicament contains a double-stranded ribonucleic acid (dsRNA) that is suitable for inhibiting by RNA interference the expression of a gene that is involved in the formation of extracellular matrix.
摘要翻译: 本发明涉及治疗纤维化疾病的药物,其中药物含有双链核糖核酸(dsRNA),其适用于通过RNA干扰参与细胞外基质形成的基因的表达。
-
公开(公告)号:US20130064879A1
公开(公告)日:2013-03-14
申请号:US13594150
申请日:2012-08-24
IPC分类号: A61K31/713 , A61K9/127 , A61P31/14 , C07H21/02
CPC分类号: C12N15/1131 , C12N2310/14 , C12N2310/53
摘要: The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is less that 30 nucleotides in length and which is substantially identical to at least a part of a 3′-untranslated region (3′-UTR) of a (+) strand RNA virus, such as HCV, as well as pharmaceutical compositions comprising the dsRNA, together with a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for treating infections and diseases caused by the replication or activity of the (+) strand RNA virus, as well as methods for inhibiting viral replication.
摘要翻译: 本发明涉及具有长度小于30个核苷酸的核苷酸序列的双链核糖核酸(dsRNA),并且其基本上与3'非翻译区(3'-UTR)的至少一部分相同 (+)链RNA病毒,例如HCV,以及包含dsRNA的药物组合物,以及药学上可接受的载体。 药物组合物可用于治疗由(+)链RNA病毒的复制或活性引起的感染和疾病以及用于抑制病毒复制的方法。
-
10.
公开(公告)号:US20120322858A1
公开(公告)日:2012-12-20
申请号:US13594140
申请日:2012-08-24
申请人: Roland Kreutzer , Stefan Limmer , Matthias John
发明人: Roland Kreutzer , Stefan Limmer , Matthias John
IPC分类号: A61K31/713 , C12N5/09 , C12N5/071 , C07H21/02 , A61P35/00
CPC分类号: C12N15/1131 , C12N15/111 , C12N2310/14 , C12N2310/53 , C12N2320/50
摘要: The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a mutant gene, comprising a first strand that has a complementary region that is complementary to at least a portion of an RNA transcript of at least part of the mutant target gene and a second strand of the dsRNA complementary or substantially complementary to the first strand. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target mutant gene, as well as for treating diseases caused by expression of the target gene. The invention also relates to methods for inhibiting the expression of a target mutant gene, as well as methods for treating diseases caused by the expression of the target gene.
摘要翻译: 本发明涉及用于抑制突变基因表达的双链核糖核酸(dsRNA),其包含第一链,该第一链具有与至少部分至少部分的RNA转录物的至少一部分互补的互补区 突变靶基因和与第一链互补或基本上互补的dsRNA的第二链。 本发明还涉及包含dsRNA和药学上可接受的载体的药物组合物。 药物组合物可用于抑制靶突变基因的表达,以及用于治疗由靶基因表达引起的疾病。 本发明还涉及抑制靶突变基因表达的方法,以及用于治疗由靶基因表达引起的疾病的方法。
-
-
-
-
-
-
-
-
-